Baxter to Acquire Seprafilm Adhesion Barriers from Sanofi for $350M

 Baxter to Acquire Seprafilm Adhesion Barriers from Sanofi for $350M

Baxter’s Eptifibatide Receives the US FDA’s Approval for Cardiovascular Diseases

Shots:

  • Baxter signs an agreement with Sanofi to acquire Seprafilm Adhesion Barrier and related assets for $350M with expected closure of transaction in Q1’20
  • The focus of the acquisition to expand Baxter’s advanced surgery portfolio that accompany the portfolio of hemostat and sealant across the hospital, including in the operating room
  • Seprafilm Adhesion Barrier is targeted for undergoing abdominal or pelvic laparotomy for reducing the incidence, extent and severity of postoperative adhesions between the abdominal wall and the underlying viscera and is marketed in the US, Japan, China, South Korea and France

Click here to­ read full press release/ article | Ref: Baxter | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post